Form 4: Cytek Legal Officer's Stock Holdings Update

Cytek Biosciences' Chief Legal Officer, Valerie Barnett, reported routine vesting of Restricted Stock Units and associated tax-related share dispositions.

Summary

• Valerie Barnett, Chief Legal Officer of Cytek Biosciences, Inc. (CTKB), reported transactions on November 18, 2025.
• Acquired a total of 24,307 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Disposed of 7,817 shares of common stock at a price of $5.53 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, beneficial ownership of common stock increased by 16,490 shares, resulting in a total of 115,641 shares directly owned.
• Remaining unvested Restricted Stock Units total 238,198 across various awards.

Sentiment

Score: 6

Explanation: The filing reflects routine, pre-scheduled compensation events (RSU vesting) and associated tax-related share dispositions. The net increase in beneficial ownership is slightly positive, indicating continued alignment, but the overall impact is neutral as it's a standard compensation mechanism.

Positives

• Increased direct beneficial ownership of common stock by 16,490 shares, demonstrating continued alignment with shareholder interests.
• Routine vesting of Restricted Stock Units indicates ongoing compensation and retention of key management.

Negatives

• A portion of vested shares (7,817 shares) was sold to cover tax obligations, which is a common practice but reduces direct ownership.

Future Outlook

Valerie Barnett holds significant unvested Restricted Stock Units, with various vesting schedules extending into future years, including quarterly vesting for one award and specific dates (May 18, August 18, November 18, March 10) for others, indicating continued long-term equity incentives.

Industry Context

This filing represents a routine insider transaction related to executive compensation, common across publicly traded companies in the biotechnology and life sciences sector like Cytek Biosciences. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minor, as it's a routine compensation event. The net increase in shares held by a key executive can be seen as a positive signal of alignment.
• Employees: Reflects standard executive compensation practices, which can influence employee perception of equity programs.

Next Steps

• Continued quarterly vesting of RSU Award (1) on August 18, November 18, February 18, and May 18.
• Continued vesting of RSU Award (2) on May 18, August 18, November 18, and March 10 of subsequent years.
• Continued vesting of RSU Award (3) on May 18, August 18, November 18, and March 10 of subsequent years.
• Continued vesting of RSU Award (4) on May 18, August 18, November 18, and March 10 of subsequent years, until fully vested.

Key Dates

Keywords

Cytek Biosciences, CTKB, Valerie Barnett, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Stock Ownership, Chief Legal Officer